---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-013555"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:19:18.304998+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI reports Multikine cuts death risk by half in target head & neck cancer patients; seeks accelerated approval

## Summary
- CEO Geert Kersten's employment extended to August 31, 2027.
- Multikine shows 28.6% absolute 5-year overall survival benefit vs control (p=0.0015) in target population.
- Hazard ratio 0.349; risk of death cut in half at 5 years in target patients.
- >35% pre-surgery tumor reductions/downstages (p<0.01) with low PD-L1 expression.
- Company plans conditional/accelerated approval worldwide without waiting for new trial.

## SEC filing metadata
- accession: 0001654954-23-013555
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495423013555/0001654954-23-013555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-013555
- JSON: https://secwatch.observer/filing/0001654954-23-013555.json
- Plain text: https://secwatch.observer/filing/0001654954-23-013555.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.